HCA-7 Colony 29

2091238, human colon, Epithelial

• UNSPSC代码: 41106514

属性

• 产品名称: HCA-7 Colony 29, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA., 02091238
• 生物来源: human colon
• 包装: tube of 5 μg 02091238-DNA-5UG; pkg of vial of cells 02091238-1VL
• 生长模式: Adherent
• 核型: Near Diploid
• 形态学: Epithelial
• 产品: Expresses Cox-2
• 受体: EGF. Parent HCA-7 cell line: wildtype APC. Known mutations:Parent HCA-7 cell line: RER phenotype, p53
• 技术: cell culture | mammalian: suitable
• 相关疾病: cancer
• 运输: dry ice
• 储存温度: −196°C

说明

细胞系来源

Human Colon Carcinoma (subpopulation isolated from the HCA-7 cell line)

细胞系描述

The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations.

DNA图谱分析

STR-PCR Data: Amelogenin: X
CSF1PO: 11,14
D13S317: 9
D16S539: 10,11
D5S818: 8,12
D7S820: 11,12
THO1: 6,7
TPOX: 8,10
vWA: 14,16

培养基

DMEM + 10% FBS + 2mM L-Glutamine + 110mg/L Sodium Pyruvate (NaP).

传代培养常规

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

其他说明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

免责声明

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.